WAP
HQL

Wealthcare Advisory Partners’s abrdn Life Sciences Investors HQL Stock Holding History

Wealthcare Advisory Partners’s Portfolio HQL Stock Details HQL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$238K Buy
11,876
+361
+3% +$6.38K ﹤0.01% 972
2026
Q1 		$187K Buy
11,515
+702
+6% +$11.7K ﹤0.01% 1028
2025
Q4 		$181K Hold
10,813
– – ﹤0.01% 1029
2025
Q3 		$168K Buy
10,813
+316
+3% +$4.33K ﹤0.01% 982
2025
Q2 		$134K Buy
10,497
+196
+2% +$2.42K ﹤0.01% 946
2025
Q1 		$131K Buy
+10,301
New +$139K ﹤0.01% 882

Other funds holding HQL

1WA
180 Wealth Advisors Federal Way, Washington $997M AUM 47.84% 1-Year Est. Return
FAM
Formidable Asset Management Cincinnati, Ohio $629M AUM 15.56% 1-Year Est. Return
PFO
PMG Family Office Plano, Texas $109M AUM 15.87% 1-Year Est. Return
DI
Decision Investments San Diego, California $110M AUM
IFG
Independent Financial Group San Diego, California $5.35B AUM 43.78% 1-Year Est. Return
MFG
Merit Financial Group Alpharetta, Georgia $16.4B AUM 25.17% 1-Year Est. Return
SFS
Shaker Financial Services Arlington, Virginia $319M AUM 3.9% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
CA
CoreCap Advisors Southfield, Michigan $3.39B AUM 31.21% 1-Year Est. Return
SIC
Salem Investment Counselors Winston Salem, North Carolina $4.03B AUM 61.49% 1-Year Est. Return

Wealthcare Advisory Partners's HQL Position: Q2 2026 in Review

Wealthcare Advisory Partners increased its abrdn Life Sciences Investors (HQL) stake by 3.1% in Q2 2026, buying an estimated $6.38K and bringing the position to 11,876 shares worth $238K. The position accounts for ﹤0.01% of the portfolio, ranked #972.

Wealthcare Advisory Partners first reported a position in HQL in Q1 2025 and has held it in 6 quarters since. 12 funds tracked by Wall St. Rank hold HQL as of Q2 2026.

  • Wealthcare Advisory Partners held 11,876 shares of abrdn Life Sciences Investors worth $238K as of Q2 2026.
  • Wealthcare Advisory Partners bought 361 abrdn Life Sciences Investors shares in Q2 2026, an estimated $6.38K.
  • abrdn Life Sciences Investors made up ﹤0.01% of Wealthcare Advisory Partners's portfolio in Q2 2026, its #972 holding.
  • Wealthcare Advisory Partners first reported a position in abrdn Life Sciences Investors in Q1 2025 and has held it in 6 quarters since.
  • 12 funds tracked by Wall St. Rank held abrdn Life Sciences Investors as of Q2 2026.

Based on Wealthcare Advisory Partners's 13F filing for Q2 2026, filed 9 Jul 2026.